Bio-Rad Laboratories 

$304.15
115
+$0.00+0% Wednesday 19:50

Statistics

Day High
304.15
Day Low
304.15
52W High
321.12
52W Low
208.36
Volume
59
Avg. Volume
-
Mkt Cap
0
P/E Ratio
50.52
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30JulExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
1.73
2.12
2.51
2.9
Expected EPS
1.747616
Actual EPS
N/A

Financials

-71.86%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
2.57BRevenue
-1.84BNet Income

Analyst Ratings

303.33Average Price Target
The highest estimate is 320.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
33%
Hold
67%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BIO-B. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Thermo Fisher Scientific
TMO
Mkt Cap175.7B
Thermo Fisher Scientific offers a broad range of products and services in the life sciences sector, directly competing with Bio-Rad's offerings in laboratory equipment and consumables.
Danaher
DHR
Mkt Cap130.44B
Danaher Corporation operates in similar segments as Bio-Rad, including life sciences and diagnostics, making them direct competitors in multiple product lines.
Illumina
ILMN
Mkt Cap24.56B
Illumina specializes in genomics and DNA sequencing technologies, competing with Bio-Rad's products in the genomics field.
Agilent Technologies
A
Mkt Cap38.25B
BioAge Labs, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing therapeutic solutions for metabolic illnesses. The company employs a distinctive technology platform alongside specialized human datasets to pinpoint potential drug targets by unraveling the molecular mechanisms underlying the aging process. Their current pipeline features azelaprag, an oral small molecule, which is undergoing Phase 1 clinical trials for obesity. Additionally, BioAge has commenced a Phase 2 clinical trial for azelaprag, investigating its efficacy in combination with tirzepatide for managing obesity specifically in older adults. Another asset under development is BGE-100, an oral, brain-penetrant small molecule designed to act as an NLRP3 antagonist, aiming to address conditions characterized by neuroinflammation. Established in 2015, BioAge Labs, Inc. operates from its headquarters in Richmond, California.
Bio-Rad Laboratories
BIO.B
Mkt Cap8.84B
Bio-Rad Laboratories Class B shares represent a different class of stock of the same company but are listed separately, directly tied to the company's performance.
Waters
WAT
Mkt Cap35.87B
Waters Corporation provides analytical instruments for the life sciences sector, competing with Bio-Rad's chromatography and mass spectrometry products.
Bruker
BRKR
Mkt Cap8.58B
Bruker Corporation is a competitor in the life science analytical and diagnostic instruments sector, directly competing with several of Bio-Rad's product lines.
Qiagen NV
QGEN
Mkt Cap7.57B
QIAGEN is a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research, competing with Bio-Rad in the diagnostics and research sectors.
Baxter International
BAX
Mkt Cap10.01B
Baxter International operates in the medical devices and life sciences fields, competing with Bio-Rad in the broader healthcare and scientific research sectors.

About

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Show more...
CEO
Mr. Norman D. Schwartz
Employees
7700
Country
United States
ISIN
US0905721082

Listings

0 Comments

Share your thoughts

FAQ

What is Bio-Rad Laboratories stock price today?
The current price of BIO-B is $304.15 USD — it has increased by +0% in the past 24 hours. Watch Bio-Rad Laboratories stock price performance more closely on the chart.
What is Bio-Rad Laboratories stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Bio-Rad Laboratories stocks are traded under the ticker BIO-B.
When is the next Bio-Rad Laboratories earnings date?
Bio-Rad Laboratories is going to release the next earnings report on July 30, 2026.
What were Bio-Rad Laboratories earnings last quarter?
BIO-B earnings for the last quarter are 1.89 USD per share, whereas the estimation was 1.97 USD resulting in a -4.21% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Bio-Rad Laboratories revenue for the last year?
Bio-Rad Laboratories revenue for the last year amounts to 2.57B USD.
What is Bio-Rad Laboratories net income for the last year?
BIO-B net income for the last year is -1.84B USD.
How many employees does Bio-Rad Laboratories have?
As of June 10, 2026, the company has 7,700 employees.
In which sector is Bio-Rad Laboratories located?
Bio-Rad Laboratories operates in the Health & Wellness sector.
When did Bio-Rad Laboratories complete a stock split?
Bio-Rad Laboratories has not had any recent stock splits.
Where is Bio-Rad Laboratories headquartered?
Bio-Rad Laboratories is headquartered in Hercules, United States.